Summary
GlobalData's Medical Devices sector report, “Refractive Surgery Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Refractive Surgery Devices currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and the number of trials for the key Refractive Surgery Devices pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Refractive Surgery Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Refractive Surgery Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Refractive Surgery Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Companies Mentioned
STAAR Surgical Company
Valeant Pharmaceuticals International Inc
Wake Forest Baptist Medical Center
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Refractive Surgery Devices Overview 5
3 Products under Development 6
3.1 Refractive Surgery Devices - Pipeline Products by Stage of Development 6
3.2 Refractive Surgery Devices - Pipeline Products by Territory 7
3.3 Refractive Surgery Devices - Pipeline Products by Regulatory Path 8
3.4 Refractive Surgery Devices - Pipeline Products by Estimated Approval Date 9
4 Refractive Surgery Devices - Pipeline Products under Development by Companies 10
4.1 Refractive Surgery Devices Companies - Pipeline Products by Stage of Development 10
4.2 Refractive Surgery Devices - Pipeline Products by Stage of Development 11
5 Refractive Surgery Devices Companies and Product Overview 12
5.1 STAAR Surgical Company Company Overview 12
5.1.1 STAAR Surgical Company Pipeline Products & Ongoing Clinical Trials Overview 12
5.2 Valeant Pharmaceuticals International Inc Company Overview 18
5.2.1 Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 18
5.3 Wake Forest Baptist Medical Center Company Overview 20
5.3.1 Wake Forest Baptist Medical Center Pipeline Products & Ongoing Clinical Trials Overview 20
6 Refractive Surgery Devices- Recent Developments 21
6.1 Mar 02, 2017: STAAR Surgical Reports Fourth Quarter 2016 Results 21
6.2 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 22
6.3 Jan 25, 2017: Novartis Plans to Spin-Off Alcon 26
6.4 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 26
6.5 Dec 19, 2016: Lensar Strategic Restructure In Partnership With Pdl Biopharma 26
6.6 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 27
6.7 Nov 10, 2016: ReVision Optics Raises USD32 Million in Venture Financing 28
6.8 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 28
6.9 Nov 03, 2016: STAAR Surgical Reports Third Quarter 2016 Results 32
6.10 Oct 12, 2016: Bausch + Lomb Booth to Feature Wet Lab During the Annual Meeting of the American Academy of Ophthalmology in Chicago 33
6.11 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 36
6.12 Sep 10, 2016: Two Studies Demonstrate Promising Results of PiXL Procedure (Photorefractive Intrastromal Corneal Collagen Cross-Linking) for Non-Invasive Treatment of Low Myopia 37
6.13 Sep 08, 2016: Avedro Appoints Dr. Reza Zadno As Chief Executive Officer 38
6.14 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 38
6.15 Aug 18, 2016: ReVision Optics Secures USD10 Million from Square 1 Bank 39
6.16 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 39
6.17 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 40
6.18 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 41
6.19 Aug 03, 2016: STAAR Surgical Reports Second Quarter 2016 Results 43
6.20 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 44
6.21 Jun 30, 2016: Wake Forest Baptist Receives Specialty Pharmacy Accreditation 45
6.22 Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 45
6.23 Jun 15, 2016: Ellex Secures China FDA Approval for Ophthalmic Treatment Lasers 46
6.24 Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 46
6.25 Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 47
6.26 May 26, 2016: Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 48
6.27 May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 48
6.28 May 18, 2016: Wake Forest Baptist Fiscal Year 2016 Third Quarter Financial Performance 49
6.29 May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 50
6.30 May 13, 2016: Wake Forest Baptist Reports Record $376.3 Million in Community Benefits during 2015 Fiscal Year 50
6.31 May 11, 2016: STAAR Surgical Reports First Quarter 2016 Results 51
7 Appendix 54
7.1 Methodology 54
7.2 About GlobalData 57
7.3 Contact Us 57
7.4 Disclaimer 57
1.1 List of Tables
Table 1: Refractive Surgery Devices - Pipeline Products by Stage of Development 6
Table 2: Refractive Surgery Devices - Pipeline Products by Territory 7
Table 3: Refractive Surgery Devices - Pipeline Products by Regulatory Path 8
Table 4: Refractive Surgery Devices - Pipeline Products by Estimated Approval Date 9
Table 5: Refractive Surgery Devices Companies - Pipeline Products by Stage of Development 10
Table 6: Refractive Surgery Devices - Pipeline Products by Stage of Development 11
Table 7: STAAR Surgical Company Pipeline Products & Ongoing Clinical Trials Overview 12
Table 8: Preloaded Injector System - Collamer ICL - Product Status 12
Table 9: Preloaded Injector System - Collamer ICL - Product Description 13
Table 10: Visian ICL Preloaded System - Product Status 13
Table 11: Visian ICL Preloaded System - Product Description 13
Table 12: Visian Implantable Collamer Lens - V5 - Product Status 14
Table 13: Visian Implantable Collamer Lens - V5 - Product Description 14
Table 14: Visian Implantable Collamer Lens V6a - Product Status 14
Table 15: Visian Implantable Collamer Lens V6a - Product Description 15
Table 16: Visian Toric Implantable Collamer Lens - Product Status 15
Table 17: Visian Toric Implantable Collamer Lens - Product Description 15
Table 18: Vision Implantable Collamer Lens V6b - Product Status 16
Table 19: Vision Implantable Collamer Lens V6b - Product Description 17
Table 20: Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 18
Table 21: BLS - 014: Refractive - Product Status 18
Table 22: BLS - 014: Refractive - Product Description 19
Table 23: Wake Forest Baptist Medical Center Pipeline Products & Ongoing Clinical Trials Overview 20
Table 24: One-Card Presbyopia System - Product Status 20
Table 25: One-Card Presbyopia System - Product Description 20
Table 26: Glossary 56
1.2 List of Figures
Figure 1: Refractive Surgery Devices - Pipeline Products by Stage of Development 6
Figure 2: Refractive Surgery Devices - Pipeline Products by Territory 7
Figure 3: Refractive Surgery Devices - Pipeline Products by Regulatory Path 8
Figure 4: Refractive Surgery Devices - Pipeline Products by Estimated Approval Date 9
